Volume 31, Issue 1, February 2013

ISSN: 0167-6997 (Print) 1573-0646 (Online)

In this issue (27 articles)

previous Page of 2

  1. No Access

    PRECLINICAL STUDIES

    Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent

    Sang Joon Shin, Jee Won Hwang, Joong Bae Ahn, Sun Young Rha… Pages 1-13
    Look Inside Get Access

  2. No Access

    PRECLINICAL STUDIES

    A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer

    J. Rodríguez-Pascual, P. Sha, E. García-García… Pages 14-19
    Look Inside Get Access

  3. No Access

    PRECLINICAL STUDIES

    Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells

    Donna M. Cartledge, Rita Colella, Lisa Glazewski, Guizhen Lu… Pages 20-29
    Look Inside Get Access

  4. No Access

    PRECLINICAL STUDIES

    Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines

    Brigette B. Y. Ma, Vivian W. Y. Lui, Crystal S. Cheung… Pages 30-38
    Look Inside Get Access

  5. No Access

    PRECLINICAL STUDIES

    Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines

    Jodi A. Muscal, Kathleen A. Scorsone, Linna Zhang… Pages 39-45
    Look Inside Get Access

  6. No Access

    PRECLINICAL STUDIES

    Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer

    Nilesh A. Patankar, Dawn Waterhouse, Dita Strutt… Pages 46-58
    Look Inside Get Access

  7. No Access

    PRECLINICAL STUDIES

    Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study

    Anne Sudaka, Antoine Susini, Cristiana Lo Nigro… Pages 59-65
    Look Inside Get Access

  8. No Access

    PRECLINICAL STUDIES

    Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases

    Teresa G. Granda, David Cebrián, Sonia Martínez… Pages 66-76
    Look Inside Get Access

  9. PHASE I STUDIES

    Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

    Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso… Pages 77-84
    Download PDF (154KB) View Article

  10. PHASE I STUDIES

    A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer

    Sil Kordes, Dick J. Richel, Heinz-Josef Klümpen… Pages 85-91
    Download PDF (181KB) View Article

  11. No Access

    PHASE I STUDIES

    Phase I trial of dasatinib and ixabepilone in patients with solid tumors

    P. Herbolsheimer, R. Kapoor, K. L. Smith, D. Perry, N. Verma… Pages 92-98
    Look Inside Get Access

  12. PHASE I STUDIES

    A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

    Thomas Yau, P. N. Cheng, Pierre Chan, William Chan, Li Chen… Pages 99-107
    Download PDF (342KB) View Article

  13. No Access

    PHASE I STUDIES

    First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours

    Yasuhito Fujisaka, Yusuke Onozawa, Takayasu Kurata… Pages 108-114
    Look Inside Get Access

  14. No Access

    PHASE I STUDIES

    A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

    A. Dasari, L. Gore, W. A. Messersmith, S. Diab, A. Jimeno… Pages 115-125
    Look Inside Get Access

  15. No Access

    PHASE I STUDIES

    Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

    Matthew Burge, Alessandra B. Francesconi, Dusan Kotasek… Pages 126-135
    Look Inside Get Access

  16. No Access

    PHASE I STUDIES

    Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

    Glen J. Weiss, Ross C. Donehower, Tara Iyengar… Pages 136-144
    Look Inside Get Access

  17. No Access

    PHASE II STUDIES

    A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma

    Christopher W. Ryan, Chacon Matias, Mark Agulnik… Pages 145-151
    Look Inside Get Access

  18. No Access

    PHASE II STUDIES

    Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer

    Keun Seok Lee, In Hae Park, Byung-Ho Nam, Jungsil Ro Pages 152-159
    Look Inside Get Access

  19. No Access

    PHASE II STUDIES

    Investigation of bendamustine HCL in a Phase 2 study in women with resistant ovarian cancer

    Amanda F. Baker, Denise J. Roe, Cynthia Laughren… Pages 160-166
    Look Inside Get Access

  20. No Access

    PHASE II STUDIES

    Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005

    J. T. Hartmann, S. Bauer, G. Egerer, M. S. Horger, H.-G. Kopp… Pages 167-174
    Look Inside Get Access
previous Page of 2